Rigel Pharmaceuticals, Inc.
RIGL
$26.55
$0.602.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1,769.22% | 124.62% | 5,887.67% | 238.79% | 1,845.86% |
| Total Depreciation and Amortization | -0.50% | -1.31% | -0.98% | 51.00% | 106.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13,965.93% | 13.48% | -1,659.94% | -36.42% | 12.28% |
| Change in Net Operating Assets | -51.98% | -220.89% | 540.73% | -667.40% | 75.13% |
| Cash from Operations | 51.55% | 10.85% | 10,011.59% | 82.19% | 332.42% |
| Capital Expenditure | 146.15% | -20.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -34.55% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -131.51% | -975.94% | -312.97% | -3,471.25% | -56.93% |
| Cash from Investing | -132.38% | -972.57% | -312.97% | -3,471.25% | -58.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 99.86% | 2,603.16% | 65.87% | 443.82% | 201.44% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -412.08% | 143.40% | 155.59% | 119.27% | 201.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -257.38% | -131.16% | -26.72% | -51.98% | 140.02% |